Mavyret occupies 85% of HCV market...sales fall 36% in 3 yrs
By Kim, Jin-Gu | translator Kim, Jung-Ju
23.02.04 05:50:42
가나다라
0
Mavyret expands its market share in the oral HCV drug market to 85% last year
Prescription sales amount falls 36% from KRW 46.5 billion in 2019 to KRW 29 billion last year
Reduction in sales attributed to the total reduction in market size... Introduction of Gilead’s Epclusa, Vosevi in the market will act as variables
▲Pic of Abbvie
Abbvie’s Mavyret has dominated the oral hepatitis C treatment market. Last year the drug increased its market share to 85%.Despite this increase in market share, the drug’s prescription performance fell 36% over the past 3 years. The analysis is that the absolute size of the Hepatitis C treatment market, which has a limited number of patients, has been decreasing due to the near-cure effect of the treatments in the market, which eventually led to a reduction in the overall market size.
◆Mavyret occupies 85% of the HCV market...prescription performance drops 36% in 3 years
According to the market research institution UBIST on the 4th, Abbvie’s oral HCV treatment
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)